American Association for Cancer Research Urges Sustained Federal Funding Amidst Promising Advances
The American Association for Cancer Research (AACR) has released its 16th annual Cancer Progress Report, highlighting significant advancements in cancer prevention, early detection, treatment, and survivorship. The report notes the FDA's approval of 11 new cancer drugs in the past year, alongside new uses for five existing therapeutics, a wearable device for pancreatic cancer, an at-home HPV self-collection kit, and several AI-based tools for early detection. Despite these breakthroughs, the AACR emphasizes that continued progress is contingent upon sustained federal investment in cancer research. The report also explores emerging areas such as the role of GLP-1 receptor agonists in cancer risk reduction, the transformative potential of artificial intelligence in research and clinical care, and the growing momentum of cancer vaccines. The AACR's mission is to prevent and cure cancer through research, education, communication, collaboration, science policy, advocacy, and funding for cancer research.